[go: up one dir, main page]

MXPA03005386A - Proteina protectora recombinante de streptococcus pneumoniae. - Google Patents

Proteina protectora recombinante de streptococcus pneumoniae.

Info

Publication number
MXPA03005386A
MXPA03005386A MXPA03005386A MXPA03005386A MXPA03005386A MX PA03005386 A MXPA03005386 A MX PA03005386A MX PA03005386 A MXPA03005386 A MX PA03005386A MX PA03005386 A MXPA03005386 A MX PA03005386A MX PA03005386 A MXPA03005386 A MX PA03005386A
Authority
MX
Mexico
Prior art keywords
streptococcus pneumoniae
protective protein
ppp
acid sequences
present
Prior art date
Application number
MXPA03005386A
Other languages
English (en)
Inventor
A Green Bruce
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MXPA03005386A publication Critical patent/MXPA03005386A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56944—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Communicable Diseases (AREA)

Abstract

La presente invencion describe secuencias de aminoacidos y secuencias de acido nucleico que se relacionan con una Proteina Pneumo Protectora (PPP) asociada con la superficie de Strepfococcus Pneurnoniae que tiene un peso molecular de aproximadamente 20 kilo Daltons (kDa). La PPP exhibe la capacidad de reducir la colonizacion de bacterias neumococicas. Por lo tanto, la presente invencion tambien pertenece a composiciones para el tratamiento y profilaxis de infecciones o inflamaciones asociadas con infeccion bacteriana.
MXPA03005386A 2000-12-28 2001-12-28 Proteina protectora recombinante de streptococcus pneumoniae. MXPA03005386A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25884100P 2000-12-28 2000-12-28
PCT/US2001/049650 WO2002053761A2 (en) 2000-12-28 2001-12-28 Recombinant protective protein from $i(streptococcus pneumoniae)

Publications (1)

Publication Number Publication Date
MXPA03005386A true MXPA03005386A (es) 2004-04-20

Family

ID=22982345

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03005386A MXPA03005386A (es) 2000-12-28 2001-12-28 Proteina protectora recombinante de streptococcus pneumoniae.

Country Status (15)

Country Link
US (4) US7118756B2 (es)
EP (2) EP2402359A1 (es)
JP (2) JP4445200B2 (es)
KR (1) KR20030074680A (es)
CN (1) CN100422210C (es)
AT (1) ATE501161T1 (es)
AU (1) AU2002227450B2 (es)
BR (1) BR0116756A (es)
CA (1) CA2432426A1 (es)
DE (1) DE60144198D1 (es)
DK (1) DK1355918T5 (es)
ES (1) ES2359625T3 (es)
IL (1) IL155726A0 (es)
MX (1) MXPA03005386A (es)
WO (1) WO2002053761A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118756B2 (en) * 2000-12-28 2006-10-10 Wyeth Recombinant protective protein from Streptococcus pneumoniae
CN1636062A (zh) 2001-04-16 2005-07-06 惠氏控股公司 编码多肽抗原的新肺炎链球菌可读框及其应用
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CN104815327A (zh) 2005-04-08 2015-08-05 惠氏有限责任公司 多价肺炎球菌多糖-蛋白质缀合物组合物
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
EP2091968A2 (en) 2006-10-26 2009-08-26 Novo Nordisk A/S Il-21 variants
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075201A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
EP3058362B1 (en) * 2013-10-18 2019-01-02 Dr. Reddy's Laboratories Limited In-vitro method for determining fate of polypeptide variant
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
CA3031797A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
EP3493837B1 (en) 2016-08-05 2022-08-31 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
KR102650073B1 (ko) 2017-01-31 2024-03-20 머크 샤프 앤드 돔 엘엘씨 스트렙토코커스 뉴모니아 혈청형 19f 유래의 협막 다당류 단백질 접합체의 제조 방법
KR20190108583A (ko) 2017-01-31 2019-09-24 머크 샤프 앤드 돔 코포레이션 다당류-단백질 접합체 제조 방법
PT3585803T (pt) 2017-02-24 2025-12-22 Merck Sharp & Dohme Formulações de vacina pneumocócica conjugada
PL3678654T3 (pl) 2017-09-07 2024-12-16 Merck Sharp & Dohme Llc Polisacharydy pneumokokowe i ich zastosowanie w immunogennych koniugatach polisacharyd-białko nośnikowe
US11116828B2 (en) 2017-12-06 2021-09-14 Merck Sharp & Dohme Corp. Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
SG11202006387QA (en) 2018-02-05 2020-07-29 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2019215216B2 (en) 2018-02-05 2025-04-17 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
GEP20247633B (en) 2018-12-19 2024-06-25 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
MX2022001241A (es) 2019-07-31 2022-04-20 Sanofi Pasteur Inc Composiciones de conjugados neumococicos multivalentes polisacarido - proteina y metodos para usar los mismos.
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
US20240390471A1 (en) 2023-05-18 2024-11-28 Merck Sharp & Dohme Llc Compounds and adjuvant formulations useful in pneumococcal vaccines

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US425330A (en) * 1890-04-08 Shutter-fastener
US4367110A (en) 1979-07-02 1983-01-04 Toppan Printing Co. Decorative laminate and a manufacturing method therefor
US4452901A (en) 1980-03-20 1984-06-05 Ciba-Geigy Corporation Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays
US4358535A (en) 1980-12-08 1982-11-09 Board Of Regents Of The University Of Washington Specific DNA probes in diagnostic microbiology
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4425330A (en) * 1981-05-20 1984-01-10 Cornell Research Foundation, Inc. Bovine mastitis vaccine and method for detecting efficacy thereof
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
DE3424893A1 (de) 1984-07-06 1986-02-06 Agfa-Gevaert Ag, 5090 Leverkusen Photographisches silberhalogenidaufzeichnungsmaterial
GB8424757D0 (en) 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
WO1989007150A1 (en) 1988-02-05 1989-08-10 The Trustees Of Columbia University In The City Of Retroviral packaging cell lines and processes of using same
JP3082204B2 (ja) 1988-09-01 2000-08-28 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 両栄養性および環境栄養性宿主域を持つ組換え体レトロウイルス
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5266477A (en) * 1990-02-02 1993-11-30 Pitman-Moore, Inc. Monoclonal antibodies which differentiate between native and modified porcine somatotropins
US5053934A (en) 1990-02-09 1991-10-01 Krebs Juergen Optical arrangement for high-powered diaprojectors
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
KR100372934B1 (ko) 1990-09-25 2003-12-24 캔탑 파마슈티칼스 리서취 리미티드 형질 상보성 세포주에 의해 생성된 바이러스 결손 백신
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5290393A (en) * 1991-01-31 1994-03-01 Nichia Kagaku Kogyo K.K. Crystal growth method for gallium nitride-based compound semiconductor
JP2666228B2 (ja) * 1991-10-30 1997-10-22 豊田合成株式会社 窒化ガリウム系化合物半導体発光素子
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US6015562A (en) 1992-09-22 2000-01-18 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
JPH06120218A (ja) * 1992-10-02 1994-04-28 Miyazaki Oki Electric Co Ltd 半導体素子の金属配線
US5578839A (en) * 1992-11-20 1996-11-26 Nichia Chemical Industries, Ltd. Light-emitting gallium nitride-based compound semiconductor device
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
KR100286699B1 (ko) * 1993-01-28 2001-04-16 오가와 에이지 질화갈륨계 3-5족 화합물 반도체 발광디바이스 및 그 제조방법
WO1994021807A2 (en) 1993-03-19 1994-09-29 Cantab Pharmaceuticals Research Limited Defective mutant non-retroviral virus (e.g. hsv) as vaccine
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5679582A (en) 1993-06-21 1997-10-21 Scriptgen Pharmaceuticals, Inc. Screening method for identifying ligands for target proteins
KR100356615B1 (ko) 1993-07-13 2003-04-03 아방티 파르마 소시에테 아노님 결함아데노바이러스벡터및유전자치료에서그의사용
JPH09501055A (ja) 1993-07-30 1997-02-04 ユニバーシティ オブ メディシン アンド デンティストリー オブ ニュージャージー 初代リンパ球への効率的遺伝子転移
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US5474905A (en) * 1993-11-24 1995-12-12 Research Corporation Technologies Antibodies specific for streptococcus pneumoniae hemin/hemoglobin-binding antigens
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2716459B1 (fr) 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
AU2194895A (en) 1994-03-25 1995-10-17 Uab Research Foundation, The Composition and methods for creating syngeneic recombinant virus-producing cells
CA2187818A1 (en) 1994-04-15 1995-10-26 Robert W. Overell Gene delivery fusion proteins
EP0804582A1 (en) * 1994-05-16 1997-11-05 The Uab Research Foundation $i(STREPTOCOCCUS PNEUMONIAE) CAPSULAR POLYSACCHARIDE GENES AND FLANKING REGIONS
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US5670798A (en) * 1995-03-29 1997-09-23 North Carolina State University Integrated heterostructures of Group III-V nitride semiconductor materials including epitaxial ohmic contact non-nitride buffer layer and methods of fabricating same
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
WO1996039036A1 (en) 1995-06-05 1996-12-12 The University Of Alabama At Birmingham Research Foundation Composition and methods for creating syngeneic recombinant virus-producing cells
FR2741358B1 (fr) 1995-11-17 1998-01-02 Centre Nat Rech Scient Production de vecteurs retroviraux par l'intermediaire de vecteurs viraux a base de virus a adn
US5987048A (en) * 1996-07-26 1999-11-16 Kabushiki Kaisha Toshiba Gallium nitride-based compound semiconductor laser and method of manufacturing the same
US6420135B1 (en) * 1996-10-31 2002-07-16 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
AU5355398A (en) * 1996-11-12 1998-06-03 Regents Of The University Of Minnesota C3 binding protein of (streptococcus pneumoniae)
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
IL133710A0 (en) 1997-06-30 2001-04-30 Rhone Poulence Rorer S A Improved method for transferring nucleic acid into the striped muscle and combination thereof
IL133708A0 (en) 1997-06-30 2001-04-30 Rhone Poulence Rorer S A Improved method for transferring nucleic acid into multicelled eukaryotic organism cells and combination thereof
BR9810500A (pt) 1997-06-30 2000-09-05 Rhone Poulenc Rorer Sa Sistema e aparelho para a transferência de ácido nucléico in vivo para o interior de células de organismos eucarióticos pluricelulares
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
JPH1187504A (ja) * 1997-09-12 1999-03-30 Toshiba Corp 半導体装置の製造方法及び配線の形成方法
EP1017828A1 (en) * 1997-09-24 2000-07-12 Regents Of The University Of Minnesota HUMAN COMPLEMENT C3-DEGRADING PROTEINASE FROM $i(STREPTOCOCCUS PNEUMONIAE)
US6013937A (en) * 1997-09-26 2000-01-11 Siemens Aktiengesellshaft Buffer layer for improving control of layer thickness
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
WO1999051259A2 (en) 1998-04-03 1999-10-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6233265B1 (en) * 1998-07-31 2001-05-15 Xerox Corporation AlGaInN LED and laser diode structures for pure blue or green emission
MXPA01003228A (es) 1998-09-30 2003-06-24 American Cyanamid Co Holotoxina de colera mutante como un coadyuvante.
US6133589A (en) * 1999-06-08 2000-10-17 Lumileds Lighting, U.S., Llc AlGaInN-based LED having thick epitaxial layer for improved light extraction
WO2001070955A2 (en) 2000-03-21 2001-09-27 Elitra Pharmaceuticals, Inc. Identification of essential genes in prokaryotes
US7118756B2 (en) * 2000-12-28 2006-10-10 Wyeth Recombinant protective protein from Streptococcus pneumoniae
CN1636062A (zh) * 2001-04-16 2005-07-06 惠氏控股公司 编码多肽抗原的新肺炎链球菌可读框及其应用

Also Published As

Publication number Publication date
US7118756B2 (en) 2006-10-10
EP2402359A1 (en) 2012-01-04
EP1355918B1 (en) 2011-03-09
US8124750B2 (en) 2012-02-28
ES2359625T3 (es) 2011-05-25
US20120141522A1 (en) 2012-06-07
ATE501161T1 (de) 2011-03-15
CN1529710A (zh) 2004-09-15
KR20030074680A (ko) 2003-09-19
BR0116756A (pt) 2005-01-04
EP1355918A2 (en) 2003-10-29
US20040052816A1 (en) 2004-03-18
DE60144198D1 (de) 2011-04-21
US20070129322A1 (en) 2007-06-07
WO2002053761A2 (en) 2002-07-11
ES2359625T9 (es) 2012-02-16
IL155726A0 (en) 2003-11-23
JP4445200B2 (ja) 2010-04-07
US20070141085A1 (en) 2007-06-21
CA2432426A1 (en) 2002-07-11
JP2009201527A (ja) 2009-09-10
US8114417B2 (en) 2012-02-14
CN100422210C (zh) 2008-10-01
EP1355918B9 (en) 2012-01-25
EP1355918A4 (en) 2006-07-19
WO2002053761A3 (en) 2003-03-27
JP2005504501A (ja) 2005-02-17
AU2002227450A2 (en) 2002-07-16
AU2002227450B2 (en) 2008-02-28
DK1355918T3 (da) 2011-05-16
DK1355918T5 (da) 2012-02-20

Similar Documents

Publication Publication Date Title
MXPA03005386A (es) Proteina protectora recombinante de streptococcus pneumoniae.
NZ549873A (en) Compounds and methods for treatment and diagnosis of chlamydial infection by stimulating an immune response
DE69331953D1 (de) Antimikrobielle polypeptide
GEP20032977B (en) Proteinase K-Resistant Surface Protein of Neisseria Meningitidis
BR9914066A (pt) Polipeptìdio degradador de c3 de complemento humano de streptococcus pneumoniae
BR9812525A (pt) Proteinase degradadora de complemento humano c3 de streptococcus pneumoniae
NZ287335A (en) Copolymer-1 composition substantially free of species of copolymer -1 with a mw of from 4 kda to 8 kda, in particular 6.25 kda to 8.4 kda
WO2002080939A8 (en) Ionene polymers and their use as antimicrobial agents
WO2001092309A3 (en) Human beta-defensin-3 (hbd-3), a highly cationic beta-defensin antimicrobial peptide
DE60332101D1 (de) Antimikrobielle zusammensetzung
WO2002090502A3 (en) Highly conserved proteins from gram-positive bacteria
GR3022052T3 (en) Dna sequences which code for virulence characteristics of --(streptococcus suis) and parts thereof, polypeptides and antibodies derived therefrom and the use thereof for the diagnosis of and protection against infection by --(s. suis) in mammals, including man
AU2858399A (en) A novel antimicrobial peptide isolated from (parasilurus asotus) and its uses
CA2295986A1 (en) Novel antimicrobial polypeptide and methods of use
AP1502A (en) Genes and proteins, and their uses.
WO2003086277A3 (en) Attenuated gram negative bacteria
RU95105983A (ru) Ингибиторы тромбина, способы их получения и фармацевтическая композиция на их основе
WO1999033871A3 (en) Essential bacterial genes and their use
WO2000037490A3 (en) Outer surface proteins, their genes, and their use
WO2002079240A3 (en) Intimins for the prevention or treatment of infections: i
WO2001049722A3 (en) New actinobacillus pleuropneumoniae outer membrane protein and its uses
WO2000029433A3 (en) 12-25-kda bacterial proteins and their 116-58 kda polymers for use e.g. in anti-tumor vaccines
WO1998014567A3 (en) Methods and compositions for inhibiting bacterial growth
WO2004011638A3 (en) Deoxyuridine 5' triphosphate nucleotidohydrolase polypeptides and structures
WO2003095604A3 (en) Purified peptide deformylase from streptococcus pneumoniae

Legal Events

Date Code Title Description
FG Grant or registration